

Instem PLC

16:38 16 Oct 2019

Instem hails contribution of informatics arm

Instem PLC (LON:INS) said it is seeing strong demand for its informatics services with the value of new orders growing by 58% to £840,000.

While the division's contribution is relatively minor at the moment, it is the pace of expansion that has excited chief executive Phil Reason and the team.

WATCH: Instem PLC reports strong demand for its informatics services Total order numbers are up by 90% during the first nine months with new business coming from 10 unique clients, compared with six a year earlier.

"We are very excited by the potential here and see this as an increasingly important part of our offering," said CEO Reason.

Instem specialises in software that streamlines and standardises the regulatory submissions process for early-stage drug development.

Informatics is a natural extension for the company. By processing and storing data it has garnered, the company has been able to develop gene- or drug-specific target safety assessments (TSAs).

TSAs are used to assess unintended adverse consequences of potential treatments before expensive investment is made and, crucially, long before they are administered to people.

Currently, this process is costly, particularly for small and mid-sized firms, which have to outsource it.

Instem's 'in silico' (computer-based) methodology is cheaper than the traditional, lab-based approach and brings with it an element of standardisation lacking currently from the current process.

In the update, the AIM-listed software group said the expansion into informatics was bringing it into contact with customers at an early stage in the drug development process.

"There is growing demand for TSA services, which determine the viability of developing drugs at an early stage, thereby ensuring that companies are able to make decisions early in the development curve and avoid unnecessary spend," investors were told.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

Price: 516

Market Cap: £86.04 m

1 Year Share Price Graph



Share Information

Code: INS

Listing: AIM

52 week	High	Low
	540	290

Sector: Software & services

Website: www.instem-iss.com

Company Synopsis:

We help our over 500 international clients efficiently access, capture, analyze, report and submit high quality regulatory data, while maintaining compliance for their products around the world. This is combined with our unique ability to generate new knowledge through the extraction and harmonization of public and proprietary sources of actionable scientific information.

action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).